Trade Summary

6 days ago, Wentworth Kory James, serving as CFO at Entrada Therapeutics, Inc. (TRDA), sold 16,477 shares at $13.01 per share, for a total transaction value of $214,379.00. Following this transaction, Wentworth Kory James now holds 121,510 shares of TRDA.

This sale represents a 12.00% decrease in Wentworth Kory James's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 9, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, March 11, 2026, 2 days after the trade was made.

Entrada Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.